Safety and Dose Study of GRN163L to Treat Patients With Chronic Lymphoproliferative Disease(CLD)

NCT00124189 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

48

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Lymphoproliferative Diseases

Interventions

DRUG: GRN163L

Sponsor

Geron Corporation